Azadirachtin
Azadirachtin is a tetranortriterpenoid limonoid compound derived from neem seeds that demonstrates significant glycemic control properties. Clinical studies show it improves insulin sensitivity by modulating glucose metabolism pathways and reducing insulin resistance markers.

Origin & History
Azadirachtin is a limonoid compound extracted primarily from the seeds of the neem tree (Azadirachta indica A. Juss.), native to the Indian subcontinent and widely cultivated in tropical regions. It belongs to the chemical class of tetranortriterpenoids and is typically obtained through solvent extraction or aqueous processing of neem seeds, leaves, or twigs, with commercial formulations standardizing azadirachtin content for pesticidal or therapeutic use.
Historical & Cultural Context
Azadirachtin-rich neem has been used for centuries in Ayurvedic medicine for antimicrobial, antiparasitic, anti-inflammatory, and antidiabetic purposes, including treatment of skin disorders and fever. Historical texts document its dual role as both a natural pesticide and therapeutic agent across traditional Asian medical systems.
Health Benefits
• Glycemic control: 12-week RCT showed dose-dependent improvements with 57.4% reduction in HOMA-IR at 500mg BID of neem extract (moderate evidence) • Insulin sensitivity: Clinical trial demonstrated significant improvements in insulin resistance markers in type 2 diabetes patients (moderate evidence) • Endothelial function: Significant reduction in %RI (p≤0.0001) shown in diabetic patients taking standardized neem extract (moderate evidence) • Pancreatic cell protection: In vitro studies show protection against oxidative stress and apoptosis in β-cells via AMPK/mTOR pathway (preliminary evidence) • Anti-parasitic activity: Inhibits Plasmodium development with IC50 of 12.4 μg/ml (preliminary evidence)
How It Works
Azadirachtin enhances glucose uptake by upregulating GLUT4 transporters and activating AMP-activated protein kinase (AMPK) pathways. The compound inhibits α-glucosidase and α-amylase enzymes, reducing postprandial glucose spikes. It also modulates insulin receptor signaling cascades, improving cellular glucose utilization and reducing hepatic glucose output.
Scientific Research
Human clinical evidence is limited to neem extracts containing azadirachtin rather than isolated compounds. A key 12-week randomized, double-blind, placebo-controlled trial (CTRI/2018/12/016666) with 80 type 2 diabetes patients showed significant glycemic improvements at 500mg BID. Preclinical studies dominate the research, including pancreatic cell protection mechanisms (PMID: 34944759).
Clinical Summary
A 12-week randomized controlled trial demonstrated dose-dependent glycemic improvements with neem extract containing azadirachtin. Participants receiving 500mg twice daily showed a 57.4% reduction in HOMA-IR (Homeostatic Model Assessment for Insulin Resistance). Clinical trials in type 2 diabetes patients revealed significant improvements in fasting glucose and insulin sensitivity markers. The evidence quality is moderate, with studies primarily conducted in diabetic populations.
Nutritional Profile
Azadirachtin is a highly oxygenated tetranortriterpenoid limonoid compound (molecular formula C35H44O16, molecular weight 720.7 g/mol) isolated primarily from neem (Azadirachta indica) seeds and leaves. It is not a macronutrient or micronutrient source itself but rather a concentrated bioactive secondary metabolite. Seed kernels from which it is extracted typically contain azadirachtin at concentrations of 0.2–0.8% dry weight (2,000–8,000 ppm), with high-quality cold-pressed neem seed oil containing approximately 300–2,500 ppm. Azadirachtin exists as multiple structural analogs: Azadirachtin A (most abundant, ~90% of total azadirachtins), Azadirachtin B (~7%), and trace amounts of variants C through K. The compound belongs to the limonoid class of tetranortriterpenoids and contains multiple functional groups including an enol ether, hemiacetal, tetrahydrofuranic ring, and tiglate ester moieties. Bioavailability is notably limited due to poor aqueous solubility (~0.5 mg/mL), rapid photodegradation (half-life of ~1 hour in direct sunlight), and thermal instability above 40°C. Oral bioavailability in mammalian systems is estimated to be low (<10%) due to first-pass metabolism and molecular complexity. The compound is typically accompanied in whole neem extracts by related limonoids including nimbin (~0.04% kernel dry weight), nimbidin (~2% kernel dry weight), salannin (~0.1% kernel dry weight), and gedunin (~0.07% kernel dry weight), which may contribute synergistic bioactivity. No significant vitamin, mineral, fiber, or protein content is attributable to azadirachtin itself as an isolated compound.
Preparation & Dosage
Clinically studied dosages are for neem extracts standardized to azadirachtin content: 125mg, 250mg, or 500mg twice daily, with 500mg BID showing superior outcomes for glycemic control over 12 weeks. No human dosage data exists for pure azadirachtin; animal studies use 25μM or equivalent to 100mg/kg neem azadirachtin. Consult a healthcare provider before starting any new supplement.
Synergy & Pairings
Chromium picolinate, Alpha-lipoic acid, Cinnamon extract, Bitter melon, Gymnema sylvestre
Safety & Interactions
Azadirachtin is generally well-tolerated at therapeutic doses, with mild gastrointestinal upset reported in some users. It may potentiate hypoglycemic effects of diabetes medications, requiring blood glucose monitoring and potential dose adjustments. Pregnancy and lactation safety data is insufficient, warranting avoidance during these periods. Individuals with autoimmune conditions should exercise caution due to potential immune system modulation.